Primary Immunodeficiency Disorders Market By Treatment Type (Immunoglobulin Therapy {Intravenous, Subcutaneous}, Stem Cell/Bone Marrow Transplant, Gene Therapy, Antibiotics and Antifungal Therapy, Other), By Disease Type (Antibody Deficiency Disorders {Common Variable Immunodeficiency, X-Linked Agammaglobulinemia, Selective IgA Deficiency}, Cellular Immunodeficiency Disorders, Complement Deficiencies, Combined Immunodeficiency Disorders), By Diagnostic Type (Genetic Testing, Blood Testing, Flow Cytometry, Other), By End-User (Hospitals, Specialty Clinics, Homecare Settings, Research Institutions), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Primary Immunodeficiency Disorders market accounted for USD 7.44 Billion in 2024 and is expected to reach USD 14.8 Billion by 2035, growing at a CAGR of around 6.45% between 2025 and 2035. Primary Immunodeficiency Disorders Market deals with rare, congenital disorders that result in impaired immune responses and recurrent and/or invasive infections.

Innovations influence the proportional-integral-derivative or PID market in treatment such as immunoglobulin therapies, stem cell transplants, and more recent gene therapies. Rising consciousness levels, better detection rates, and improved accessibility to healthcare services drive the market. The growing number of PID cases worldwide and the growing need for the individual approach also contribute to the Primary Immunodeficiency Disorders Market growth.

Report Scope:

Market Dynamics

Increasing awareness and diagnosis rates due to advancements in genetic testing technologies

The primary immunodeficiency disorders market is growing due to enhanced awareness and early diagnosis, primarily spreading due to the availability of advanced genetic tests. These technologies mean that there is increased accuracy in the diagnosis of PID and drainage of the pelvic cavity, which therefore can be done earlier, with greater patient-specific approaches to dealing with the patients. By identifying specific genetic abnormalities that lead to immunodeficiency, clinicians are now able to provide treatments for illnesses that were previously incurable because of inadequate evaluation methods.

The potential for genetic testing for PIDs has raised awareness among patients and healthcare professionals. Thus, as more individuals seek the tests, awareness of genetic testing and early detection has increased, particularly in industrialized nations. New treatment methods that eliminate the fundamental causes of diseases through genetic therapy have also been developed as a result of genetic diagnostics.

Growing demand for immunoglobulin therapies as a primary treatment option globally

The primary immunodeficiency disorders market is increasing its dependence on immunoglobulin therapies as the first line of treatment across the world. IVIG and SCIG are currently the most used immunoglobulin therapies for patients with PIDs. Patients with compromised immune systems benefit from these treatments since their bodies will be more susceptible to several pathogens if they are unable to produce these vital proteins. As a result, they improve life quality.

Because some subcutaneous immunoglobulin therapies allow patients to deliver the therapy at home with greater compliance than hospital admissions, their convenience is essential. There has been a rise in the use of immunoglobulin treatments as a result of healthcare systems reporting better patient regimens. The growth of the primary immunodeficiency disorders market is still influenced by growing awareness of immunoglobulin treatments as an essential part of PID treatment.

High costs of advanced therapies like gene therapy and stem cell transplantation

The primary immunodeficiency disorders (PID) market has to work around the fact that new clear-cut treatments like gene therapy or stem cell transplantation can be significantly expensive. These novel therapies, though providing the possibility of a cure for the most extreme weakness of the immune system, are costly to produce and deliver. Recent studies show that other potential treatments, such as stem cell transplants, also come with very high costs due to their specialized requirements, such as facilities and the medical human resources needed. This factor contributes to limiting the availability of these medicines because they are too costly for early emerging nations to afford.

Furthermore, exorbitant prices restrict market growth by skewing treatment accessibility among different socioeconomic groups. Since new, reasonably priced treatment methods and expanded insurance coverage may lower the highly high computational treatment cost, primary immunodeficiency disorders may see an increase in the usage of these cutting-edge treatments.

Development of curative gene therapies targeting specific severe immunodeficiency disorders worldwide

The primary immunodeficiency disorders (PID) market is evolving fundamentally due to the availability of curative gene therapies targeting certain particularly severe immunodeficiency diseases. Because they address the genetic basis of the illness, therapies like stem cell and gene therapies, which include the treatment of SCID, can offer a long-term solution. This is a creative approach that is altering the management of PIDs and even offering hope for a cure for some diseases that were previously thought to be incurable.

Anticipated cures in the form of curative gene therapies are also being watched as a similar amount of investment and focus is directed toward genetically targeted treatments for other severe PIDs. Based on clinical trials, gene therapies are likely to gain popularity as new treatment methods for patients, increasing the availability of treatment options around the world. As gene therapy gains approvals and partnerships, it is expected to redefine the management of the Primary Immunodeficiency Disorders Market for immunocompromised patients.

Expansion of homecare solutions with subcutaneous immunoglobulin (SCIG) administration gaining popularity

The disease area of Primary Immunodeficiency Disorders (PID) has experienced the growth of homecare solutions, where SCIG administration is growing. SCIG treatment enables patients to afford immunoglobulin at home while still receiving treatment, a progressive compared to the intravenous immunoglobulin (IVIG) method. This change in focus towards homecare products is even more convenient for those patients who need to undergo multiple treatments over several weeks because there is no need for frequent hospitalizations and long stays in a healthcare center.

The increasing trend in the utilization of SCIG therapy is due to the enhancement in the formulation of products provided in the market, which has reduced the painful nature of subcutaneous administration. As the caregivers are better informed and the patients themselves embrace the treatment regimens, increasingly, patients with PID are shifting to SCIG than to IVIG. Moreover, the difference in price between the homecare solutions and numerous hospital treatments is also attributed to increased demand for SCIG.

Industry Experts Opinion

"PIDs, though often unnoticed, can significantly impact a child's health. Early diagnosis and timely treatment of primary immune deficiencies can help these children to lead a good quality life. Awareness is not only important for treatment but also for prevention. We envision a future where every child with PID can lead a healthy and fulfilling life."

• Dr. Revathi Raj, Senior Consultant, Apollo Cancer Centre, Chennai

"Primary Immunodeficiency is a group of over 400 disorders that impair the immune system, making children susceptible to recurrent infections, allergies, and other health complications. While the immediate concerns often revolve around managing infections, research shows that children with PI are also at an elevated risk of developing autoimmune diseases and certain types of cancers."

• Dr Preeti Anand, Senior Consultant, Max Smart Super Specialty Hospital, Saket, New Delhi,

Segment Analysis

Based on Treatment Type, the Primary Immunodeficiency Disorders Market has been divided into stem cell/bone marrow transplants, gene therapies, antibiotics/antifungal therapies, and others. The segment is heavily monitored by immunoglobulin therapy with variations like intravenous and subcutaneous. The rising popularity of SCIG therapy will be due to the easy portability of the product for home use and better patient compliance.

Gene therapy could be said to be an innovative treatment so far being developed for curing severe diseases such as SCID backed up with genetic progression. Stem cell/bone marrow transplants are on the up as a treatment for certain conditions, while Antibiotics and antifungal agents are still necessary in the management of PID patients’ infections. The factors that are driving this segment include a growing incidence, innovation, and a rising need for personalized treatment.

Based on Disease Type, the Primary Immunodeficiency Disorders Market is divided into Antibody Deficiency Disorders, Cellular Immunodeficiency Disorders, Complement Deficiencies, and Combined Immunodeficiency Disorders collectively. The major share involves antibody deficiency disorders, CVID, and XLA patients due to typical immunoglobulin preparations.

Primary T cell and B cell immunodeficiencies, such as SCID, are emerging as more people seek outside treatments given advancement in gene therapy. Again, complement deficiencies and combined immunodeficiencies, even though are rare, benefit from diagnostics that compel early diagnosis. Its driving forces are, therefore, raising knowledge, enhanced diagnostic measures, as well as the availability of advanced treatment in the developed and developing world. These PID types’ increasing awareness creates a need for more focused therapies and individualized approaches for treatment.

Regional Analysis

The North American primary immunodeficiency disorders market is leading because of proper healthcare infrastructure, increased awareness, and increased R&D investments. Immunoglobulin and gene therapy are part of the other third-generation treatments that have the highest market share in the United States. New entries include Hizentra® for CIDP and such extensions in gene therapy front runners as Orchard Therapeutics and Bluebird Bio. Positive measures, like the Jeffrey Modell Foundation, work for the enhancement of the diagnosis frequency as well as for the provision of treatments. This is because the region has many large market players, such as CSL Behring, Takeda, and Grifols, to augment the position of the region as a center of PID care.

The Asia-Pacific primary immunodeficiency disorders market is rapidly growing due to factors such as an increase in awareness, an improvement in healthcare infrastructure, and healthcare costs. In China and India, the epidemiology of rare diseases is on the rise, through the support of governmental policies and advancements in diagnostic tests. Solutions in this area are subcutaneous immunoglobulin (SCIG) therapies that are customized for respective populations and partnerships between key global retailers and regional healthcare organizations. The availability of treatment is being made easier by increased clinical trials and investment by international firms such as Octapharma and Takeda. The objective of the present region is based on the identified extensive and untapped patient base and the increasing rate of innovative technology implementation.

Competitive Landscape

The intensiveness of competition in the Primary Immunodeficiency Disorders (PID) Market comes from the strategic positioning of dominant pharmaceutical organizations and growing biotechnology companies working on novel agents. Market leaders are CSL Behring, Takeda Pharmaceuticals, Grifols S.A., and Octapharma AG, which together offer a set of immunoglobulin solutions (Hizentra, Gammagard, Gamunex-C). Some more firms like Orchard Therapeutics and Bluebird Bio are working on gene therapy to provide cures for certain PIDs like SCID, etc.

 Possible strategies include focusing on new formulation development through capital expenditures on research & development, horizontal integration through forming strategic partnerships, and vertical integration through acquisitions. The latest developments in AAV gene therapy revealed by Rocket Pharmaceuticals tackle fundamental genetic disorders, a revolutionary change in disease management strategies. This competitive dynamic is likely to increase with steadily rising interest in curative and individual approaches.

Primary Immunodeficiency Disorders Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, The FDA authorized X4 Pharmaceuticals' mavorixafor, also known as Xolremdi, for the treatment of WHIM syndrome, a rare primary immunodeficiency. The CXCR4 receptor antagonist Mavorixafor lowers infection rates and increases white blood cell counts in patients. It significantly raised neutrophils and lymphocytes, lowered antibiotic use, and reduced infections by 60% in phase 3 research.
• In April 2023, The FDA approved Takeda's Hyqvia to treat primary immunodeficiency (PI) in children ages 2 to 16. Pediatric patients now have more alternatives thanks to this enhanced approval, which makes monthly subcutaneous therapy convenient. The decision was made in response to Phase 3 trial data that showed comparable safety to adult use and a decrease in major bacterial infections.

Report Coverage:

By Treatment Type

• Immunoglobulin Therapy
  • Intravenous
  • Subcutaneous
• Stem Cell
• Gene Therapy
• Antibiotics and Antifungal Therapy
• Other

By Disease Type

• Antibody Deficiency Disorders
  • Common Variable Immunodeficiency
  • X-Linked Agammaglobulinemia
  • Selective IgA Deficiency
• Cellular Immunodeficiency Disorders
• Complement Deficiencies
• Combined Immunodeficiency Disorders

By Diagnostic Type

• Genetic Testing
• Blood Testing
• Flow Cytometry
• Other

 By End-User

• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutions

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• CSL Behring
• Takeda Pharmaceuticals
• Grifols S.A.
• Octapharma AG
• Kedrion Biopharma
• Pfizer Inc.
• Sanofi
• Biotest AG
• Orchard Therapeutics
• Bluebird Bio
• Rocket Pharmaceuticals
• Avrobio
• ADMA Biologics
• LFB S.A.
• China Biologic Products Holdings, Inc.
• Bio Products Laboratory
• Prothya BioSolutions
• Horizon Therapeutics

Frequently Asked Questions (FAQs)